Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Qualigen Therapeutics, Inc. (RTTR) since 2015 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Qualigen Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1460702.
Total stock buying since 2015: $8,502,839.
Total stock sales since 2015: $124,100.
Total stock option exercises since 2015: $75,000.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2022 | 60,000 | $35,700 | 0 | $0 | 0 | $0 |
| 2021 | 26,205 | $43,766 | 0 | $0 | 0 | $0 |
| 2020 | 10,000 | $32,633 | 537,500 | $124,100 | 500,000 | $75,000 |
| 2018 | 19,751 | $40,292 | 0 | $0 | 0 | $0 |
| 2017 | 10,406,000 | $19,168 | 0 | $0 | 0 | $0 |
| 2016 | 40,000 | $61,280 | 0 | $0 | 0 | $0 |
| 2015 | 1,654,000 | $8,270,000 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2022-06 | 60,000 | $35,700 | 0 | $0 | 0 | $0 |
| 2021-08 | 8,000 | $9,800 | 0 | $0 | 0 | $0 |
| 2021-04 | 18,205 | $33,966 | 0 | $0 | 0 | $0 |
| 2020-12 | 4,000 | $11,740 | 0 | $0 | 0 | $0 |
| 2020-11 | 6,000 | $20,893 | 0 | $0 | 0 | $0 |
| 2020-03 | 0 | $0 | 537,500 | $124,100 | 0 | $0 |
| 2020-02 | 0 | $0 | 0 | $0 | 500,000 | $75,000 |
| 2018-08 | 19,751 | $40,292 | 0 | $0 | 0 | $0 |
| 2017-10 | 10,375,000 | $0 | 0 | $0 | 0 | $0 |
| 2017-05 | 31,000 | $19,168 | 0 | $0 | 0 | $0 |
| 2016-01 | 40,000 | $61,280 | 0 | $0 | 0 | $0 |
| 2015-06 | 1,654,000 | $8,270,000 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2022-06-22 | Poirier Michael S. (Chairman and CEO) | Buy | 30,000 | .57 | 17,100 |
| 2022-06-14 | Broidrick Amy S. (President/CSO) | Buy | 30,000 | .62 | 18,600 |
| 2021-08-19 | Kruger Kurt H | Buy | 8,000 | 1.23 | 9,800 |
| 2021-04-26 | Broidrick Amy S. (EVP, Chief Strategy Officer) | Buy | 4,500 | 2.03 | 9,135 |
| 2021-04-20 | Poirier Michael S. (Chairman, CEO & President) | Buy | 11,005 | 1.80 | 19,809 |
| 2021-04-16 | Lotz Christopher L. (Vice President of Finance, CFO) | Buy | 2,700 | 1.86 | 5,022 |
| 2020-12-29 | Kruger Kurt H | Buy | 4,000 | 2.94 | 11,740 |
| 2020-11-23 | Kruger Kurt H | Buy | 4,600 | 3.46 | 15,925 |
| 2020-11-20 | Kruger Kurt H | Buy | 1,400 | 3.55 | 4,968 |
| 2020-03-12 | Doyle Noah (Director) | Sale | 500,000 | .22 | 110,000 |
| 2020-03-04 | Ritter Ira E. (COB, CSO) | Sale | 18,750 | .38 | 7,050 |
| 2020-03-04 | Ritter Andrew J (CEO and President) | Sale | 18,750 | .38 | 7,050 |
| 2020-02-25 | Doyle Noah (Director) | Option Ex | 500,000 | .15 | 75,000 |
| 2018-08-17 | Foehr Matthew W (Director) | Buy | 19,751 | 2.04 | 40,292 |
| 2017-10-03 | Ritter Ira E. (Exec. Chairman, CSO) | Buy | 187,500 | .00 | 0 |
| 2017-10-03 | Doyle Noah (Director) | Buy | 5,000,000 | .00 | 0 |
| 2017-10-03 | Ritter Andrew J (President) | Buy | 187,500 | .00 | 0 |
| 2017-10-03 | Javelin Venture Partners, L.p. (10% Owner) | Buy | 5,000,000 | .00 | 0 |
| 2017-05-18 | Foehr Matthew W (Director) | Buy | 18,000 | .62 | 11,160 |
| 2017-05-11 | Step Michael D (CEO) | Buy | 13,000 | .62 | 8,008 |
| 2016-01-08 | Foehr Matthew W | Buy | 13,000 | 1.64 | 21,320 |
| 2016-01-07 | Step Michael D (CEO) | Buy | 27,000 | 1.48 | 39,960 |
| 2015-06-24 | Doyle Noah (Director) | Buy | 800,000 | 5.00 | 4,000,000 |
| 2015-06-24 | Javelin Venture Partners, L.p. (10% Owner) | Buy | 800,000 | 5.00 | 4,000,000 |
| 2015-06-24 | Proehl Gerald T (Director) | Buy | 50,000 | 5.00 | 250,000 |
| 2015-06-24 | Foehr Matthew W (Director) | Buy | 4,000 | 5.00 | 20,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of RTTR listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Qualigen Therapeutics, Inc. (symbol RTTR, CIK number 1460702) see the Securities and Exchange Commission (SEC) website.